This article discusses and compares statistical designs of basket trial, from both frequentist and Bayesian perspectives. Baskets trials are used in oncology to study interventions that are developed to target a specific feature (often genetic alteration or immune phenotype) that is observed across multiple tissue types and/or tumor histologies. Patient heterogeneity has become pivotal to the development of non-cytotoxic treatment strategies. Treatment targets are often rare and exist among several histologies, making prospective clinical inquiry challenging for individual tumor types. More generally, basket trials are a type of master protocol often used for label expansion. Master protocol is used to refer to designs that accommodates multiple targets, multiple treatments, or both within one overarching protocol. For the purpose of making sequential decisions about treatment futility, Simon's two-stage design is often embedded within master protocols. In basket trials, this frequentist design is often applied to independent evaluations of tumor histologies and/or indications. In the tumor agnostic setting, rarer indications may fail to reach the sample size needed for even the first evaluation for futility. With recent innovations in Bayesian methods, it is possible to evaluate for futility with smaller sample sizes, even for rarer indications. Novel Bayesian methodology for a sequential basket trial design based on predictive probability is introduced. The Bayesian predictive probability designs allow interim analyses with any desired frequency, including continual assessments after each patient observed. The sequential design is compared with and without Bayesian methods for sharing information among a collection of discrete, and potentially non-exchangeable tumor types. Bayesian designs are compared with Simon's two-stage minimax design.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345361PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0272367PLOS

Publication Analysis

Top Keywords

basket trials
12
simon's two-stage
12
predictive probability
12
bayesian
8
two-stage design
8
bayesian predictive
8
basket trial
8
tumor histologies
8
tumor types
8
master protocol
8

Similar Publications

Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. We sought to determine the objective response rate of combination durvalumab (D) plus tremelimumab (TM) in parallel cohorts of patients with carefully selected rare cancer types in which these agents had not previously been evaluated in phase II trials and for which there was clinical or biological rationale for dual immune checkpoint inhibitor therapy to be active.

Methods: We designed a multi-centre, non-blinded, open-label phase II basket trial with each of the following 8 rare cancers considered a separate phase II trial: salivary carcinoma, carcinoma of unknown primary (CUP) with tumour infiltrating lymphocytes and/or expressing PD-L1, mucosal melanoma, acral melanoma, osteosarcoma, undifferentiated pleomorphic sarcoma, clear cell carcinoma of the ovary (CCCO) or squamous cell carcinoma of the anal canal (SCCA).

View Article and Find Full Text PDF

Reframing risks in rare diseases: economics of networks, spillovers, and scale.

Front Pharmacol

December 2024

Binera, Inc. Consulting for United States Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), Washington, DC, United States.

Rare diseases affect over three hundred million individuals globally. Investment in research and development remains incommensurate with the challenges rare diseases pose. Further investment in information sharing platforms to promote common and standardized network technologies for rare disease is needed.

View Article and Find Full Text PDF

Evaluation of cottonseed oil as a substitute for fish oil in the commercial diet for juvenile swimming crabs ().

Anim Nutr

December 2024

Laboratory of Fish and Shellfish Nutrition, School of Marine Sciences, Ningbo University, Ningbo 315211, China.

A six-week feeding trial was carried out to determine the feasibility of cottonseed oil (CSO) as a viable substitute for fish oil (FO) in the commercial diet of swimming crabs. Ninety healthy swimming crabs (initial body weight 34.28 ± 0.

View Article and Find Full Text PDF

Background: Endoscopic sphincterotomy (ES) for bile duct stones (BDS) can cause basket impaction with stone, complicating the procedure. In this study, we evaluated the utility and safety of small incision ES combined with endoscopic papillary balloon dilation (sES + EPBD) (balloon dilated up to the stone size), compared with ES alone for BDS <12 mm.

Methods: The primary endpoint was the frequency of mechanical lithotripsy (ML), indicating the risk of basket impaction with stone; however, the secondary endpoints were procedure time, successful stone removal, and early adverse events.

View Article and Find Full Text PDF
Article Synopsis
  • Stent dislodgement is a rare but difficult complication during heart procedures, and existing treatment methods are not very effective.
  • This study tested a new self-expanding basket (SEB) catheter designed to retrieve dislodged stents without causing additional injury or needing surgery.
  • In a small trial with 6 patients, the SEB catheter successfully retrieved all dislodged stents, with no safety issues reported, indicating it may be a promising solution, but more extensive research is needed.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!